Parabilis Medicines/$PBLS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Parabilis Medicines
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
- Ticker
- $PBLS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 145
- Headquarters
- Cambridge, United States
- Website
- parabilismed.com
PBLS Metrics
BasicAdvanced
$3.5B
-
-$23.45
-
-
Price and volume
Market cap
$3.5B
52-week high
$42.49
52-week low
$22.66
Average daily volume
1M
Financial strength
Current ratio
17.909
Quick ratio
17.834
Long term debt to equity
0.032
Total debt to equity
0.045
Interest coverage (TTM)
-139.58%
Profitability
EBITDA (TTM)
-169.114
Gross margin (TTM)
-8,750.68%
Net profit margin (TTM)
-115,224.32%
Operating margin (TTM)
-115,907.43%
Management effectiveness
Valuation
Price to revenue (TTM)
1,904.794
Price to book
3.36
Price to tangible book (TTM)
3.36
Price to free cash flow (TTM)
-2.506
Free cash flow yield (TTM)
-39.90%
Free cash flow per share (TTM)
-11.385
Growth
What the Analysts think about PBLS
Analyst ratings (Buy, Hold, Sell) for Parabilis Medicines stock.
Analyst projections of the future price of Parabilis Medicines stock.
Bulls say / Bears say
In desmoid tumours, 14 of 19 patients with at least two follow-up scans had an objective response, and all 25 response-evaluable patients showed some tumour reduction. This early signal gives zolucatetide a credible path towards its planned pivotal trial. (SEC)
Zolucatetide has also shown an early signal in familial adenomatous polyposis: two patients had marked reductions in duodenal polyp burden. Parabilis has now started a dedicated dose-ranging cohort to test this opportunity further. (BioSpace)
The Regeneron collaboration brought Parabilis $125 million in upfront consideration and equity investment, with further milestone payments and royalties possible. The company reported $1.1 billion in cash and marketable securities, which it expects to fund operations into 2030. (Parabilis Medicines)
The desmoid response rate is based on only 19 patients with at least two scans in an ongoing Phase 1/2 study, rather than a randomised comparison. The result may not predict how well the drug performs in a pivotal trial. (SEC)
Dose selection remains a risk: the company’s disclosed data show greater toxicity at higher doses, while its dose-optimisation work is intended to determine the regimen for a planned Phase 3 trial. A tolerable, effective dose is not yet established in pivotal testing. (SEC, Parabilis Medicines)
Parabilis remains pre-commercial and reported a $52.5 million net loss for the second quarter. Its prospects therefore depend on clinical and regulatory success before it can establish meaningful product sales. (Parabilis Medicines, SEC)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.
PBLS Financial Performance
Revenues and expenses
PBLS Earnings Performance
Company profitability
Upcoming events
No upcoming events
PBLS News
AllArticlesVideos
Funds containing PBLS
Fund name | Fund size | $PBLS weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.04% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.